ASH vs IFF: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ASH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASH and IFF share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASH and IFF exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ashland Inc. is a Wilmington, Delaware based global specialty chemicals company that operates through four segments: Life Sciences (pharma excipients and nutrition), Personal Care (skin, hair, and biofunctionals), Specialty Additives (cellulosic and rheology modifiers used in coatings, construction, and energy), and Intermediates. The company sells performance ingredients rather than commodity chemicals, competing on formulation know-how, regulatory support, and security of supply into consumer and healthcare end markets.

Full ASH guide

International Flavors & Fragrances makes the taste, scent and functional ingredients that go into other companies' products: flavor systems for beverages, snacks and dairy, fine and consumer fragrances, enzymes, cultures, probiotics and soy proteins. The company traces to 1833 and reached its current scale through the 2018 Frutarom acquisition and the February 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division, a roughly $26 billion combination that made IFF one of the four global ingredient houses alongside Givaudan, dsm-firmenich and Symrise. As of the second quarter of 2026 it reports three continuing segments, Taste (~$688 million of quarterly sales), Health & Biosciences (~$601 million) and Scent (~$665 million), after moving the Food Ingredients and Soy Crush businesses into discontinued operations.

Full IFF guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ASH drivers: Specialty additives and volume recovery; Activist campaign and possible sale.
• IFF drivers: The Food Ingredients sale and the capital return attached to it; Deleveraging from the DuPont merger is essentially complete.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Ashland is exposed to cyclical demand in coatings, construction, and energy, and fiscal 2025 showed how destocking can sharply cut volumes and earnings. For IFF, the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ASH if you believe its drivers more; IFF if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASH and IFF guides.

ASH. Ashland carries an enterprise value near $3.7 billion against roughly $1.8 billion of revenue, valuing it on a specialty-margin and recovery basis rather than trailing GAAP earnings, which were negative in fiscal 2025 due to impairments and a divestiture. The stock traded in the mid-$60s in mid-2026 within a roughly $46 to $68 52-week range, and analyst price targets clustered near the high-$60s. The ~3 percent dividend is covered by cash flow despite the GAAP loss.

IFF. The two revenue figures are not a contradiction: trailing revenue of ~$10.8 billion covers the whole company, while 2026 guidance of ~$7.4 billion to ~$7.6 billion covers only the three segments IFF is keeping, since Food Ingredients and the Soy Crush businesses moved to discontinued operations in the second quarter. Trailing GAAP EPS of ~$1.08 puts the shares near 78 times earnings, a number distorted by amortization and disposal charges, which is why the forward multiple of roughly 25 times is the one most analysts quote. Enterprise value of about $26.6 billion against ~$2.06 billion of trailing credit adjusted EBITDA works out near 13 times, while Food Ingredients is being sold at roughly 8 times its own EBITDA.

Headline figures (approximate, JULY 2026): ASH shows revenue (fy2025) ~$1.8B, fy2026 sales guidance ~$1.84B-$1.91B, market cap ~$2.9B, enterprise value ~$3.7B; IFF shows revenue (ttm, all businesses) ~$10.8B, fy 2026 sales guidance (continuing operations) ~$7.4B to ~$7.6B, q2 2026 adjusted operating ebitda margin ~20.9%, adjusted eps ex-amortization (first half 2026) ~$1.74.

ASH and IFF are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASH and IFF exposure against your real portfolio. It is not an investment adviser.